Literature DB >> 19648385

Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

John P Bida1, Robert A Kyle, Terry M Therneau, L Joseph Melton, Matthew F Plevak, Dirk R Larson, Angela Dispenzieri, Jerry A Katzmann, S Vincent Rajkumar.   

Abstract

OBJECTIVE: To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS. PATIENTS AND METHODS: Serum samples were obtained from 77% (21,463) of the 28,038 enumerated residents in Olmsted County, Minnesota. Informed consent was obtained from patients to study 17,398 samples. Among 17,398 samples tested, 605 cases of MGUS and 16,793 negative controls were identified. The computerized Mayo Medical Index was used to obtain information on all diagnoses entered between January 1, 1975, and May 31, 2006, for a total of 422,663 person-years of observations. To identify and confirm previously reported associations, these diagnostic codes were analyzed using stratified Poisson regression, adjusting for age, sex, and total person-years of observation.
RESULTS: We confirmed a significant association in 14 (19%) of 75 previously reported disease associations with MGUS, including vertebral and hip fractures and osteoporosis. Systematic analysis of all 16,062 diagnostic disease codes found additional previously unreported associations, including mycobacterium infection and superficial thrombophlebitis.
CONCLUSION: These results have major implications both for confirmed associations and for 61 diseases in which the association with MGUS is likely coincidental.

Entities:  

Mesh:

Year:  2009        PMID: 19648385      PMCID: PMC2719521          DOI: 10.1016/S0025-6196(11)60518-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  111 in total

1.  Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study.

Authors:  Bertrand Arnulf; Djaouida Bengoufa; Emile Sarfati; Marie-Elisabeth Toubert; Véronique Meignin; Jean-Claude Brouet; Jean-Paul Fermand
Journal:  Arch Intern Med       Date:  2002-02-25

2.  Monoclonal paraprotein may interfere with the Roche direct HDL-C Plus assay.

Authors:  Nadine Kadri; Pierre Douville; Pierre Lachance
Journal:  Clin Chem       Date:  2002-06       Impact factor: 8.327

3.  The patient record in epidemiology.

Authors:  L T Kurland; C A Molgaard
Journal:  Sci Am       Date:  1981-10       Impact factor: 2.142

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review.

Authors:  V Lamboley; Laurent Zabraniecki; P Sie; J Pourrat; Bernard Fournié
Journal:  Joint Bone Spine       Date:  2002-01       Impact factor: 4.929

6.  Monoclonal gammopathies in Sézary syndrome: a report of four new cases and a review of the literature.

Authors:  P M Kövary; L Suter; E Macher; H Niedorf; E Grundmann; O Lukitsch; J Herzberg; H Intorp; E Schürmeyer; D Kamanabroo; H Losse
Journal:  Cancer       Date:  1981-08-01       Impact factor: 6.860

7.  [Transitory IgM monoclonal gammopathy associated with brucellosis and tuberculosis (author's transl)].

Authors:  V Vargas; J D Pedreira; J Vilaseca; F Ramos; M J Rodrigo; J Guardia
Journal:  Med Clin (Barc)       Date:  1981-10-10       Impact factor: 1.725

8.  Pyoderma gangrenosum: clinical and laboratory findings in 15 patients with special reference to polyarthritis.

Authors:  P J Holt; M G Davies; K C Saunders; G Nuki
Journal:  Medicine (Baltimore)       Date:  1980-03       Impact factor: 1.889

9.  Monoclonal gammopathy in carcinoma of the colon.

Authors:  H P Chen; J A Carroll
Journal:  Am J Clin Pathol       Date:  1980-04       Impact factor: 2.493

10.  Non-IgM monoclonal gammopathy in patients with Sjögren's syndrome.

Authors:  S Sugai; S Konda; Y Shoraski; T Murayama; T Nishikawa
Journal:  Am J Med       Date:  1980-06       Impact factor: 4.965

View more
  67 in total

1.  Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Authors:  Massimo La Raja; Monica Barcobello; Nicola Bet; Paolo Dolfini; Marina Florean; Federica Tomasella; Vincenzo De Angelis; Luca Mascaretti
Journal:  Blood Transfus       Date:  2012-03-28       Impact factor: 3.443

Review 2.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 3.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

4.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

Review 5.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

6.  Schnitzler syndrome: an under-diagnosed clinical entity.

Authors:  Tania Jain; Chetan P Offord; Robert A Kyle; David Dingli
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

Review 7.  Monoclonal gammopathy of undetermined significance.

Authors:  Sébastien Anguille; Christian Bryant
Journal:  CMAJ       Date:  2013-05-21       Impact factor: 8.262

8.  Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients.

Authors:  L E Roeker; D R Larson; R A Kyle; S Kumar; A Dispenzieri; S V Rajkumar
Journal:  Leukemia       Date:  2013-02-05       Impact factor: 11.528

9.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 10.  What is the significance of monoclonal gammopathy of undetermined significance?

Authors:  Catherine Atkin; Alex Richter; Elizabeth Sapey
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.